GLP1R and metabolic dysfunction-associated steatohepatitis: This discrepancy may be explained by: duration of the treatment (i.e. 8 hours vs. 12-weeks therapy in our study); administration of treatment (i.e. intravenous native GLP-1 vs. subcutaneous GLP-1 analogue in our study); and the fact that the Segieri et al. utilised healthy volunteers, as opposed to patients with biopsy-confirmed NASH; and the reliance on global lipolysis readouts rather than localised abdominal adipose (SAT) tissue sampling (i.e. microdialysis).